Trial reportJournal of clinical hypertension (Greenwich, Conn.)2011
Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.
Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Impact of Antihypertensive Agents on Central Systolic Blood Pressure and Augmentation Index: A Meta-Analysis.American journal of hypertension · 2016Pooled it
- Meta-analysis of the comparative effects of different classes of antihypertensive agents on brachial and central systolic blood pressure, and augmentation index.British journal of clinical pharmacology · 2013Pooled it
- Central blood pressure for the management of hypertension: Is it a practical clinical tool in current practice?Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Role of aliskiren on arterial stiffness and endothelial function in patients with primary hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2014Trial
- Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.Vascular health and risk management · 2014Trial
- Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Aliskiren alone or in combination with hydrochlorothiazide in Hispanic/Latino patients with systolic blood pressure 160 mm Hg to <180 mm Hg (Aliskiren Alone or in Combination with Hydrochlorothiazide in Patients with Stage 2 Hypertension to Provide Quick Intensive Control of Blood Pressure [ACQUIRE] substudy).Journal of clinical hypertension (Greenwich, Conn.) · 2012Trial
- Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus.Journal of clinical hypertension (Greenwich, Conn.) · 2011Trial
- The Role of Central Blood Pressure Monitoring in the Management of Hypertension.Current cardiology reports · 2018Review
- Renin Inhibition with Aliskiren: A Decade of Clinical Experience.Journal of clinical medicine · 2017Review
- Arterial Stiffness in Treated Hypertensive Patients With White-Coat Hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2017Article
- Aortic stiffness: pathophysiology, clinical implications, and approach to treatment.Integrated blood pressure control · 2014Review
- Aliskiren, amlodipine and hydrochlorothiazide triple combination for hypertension.Expert review of cardiovascular therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficacy of antihypertensive agents on central blood pressure (BP) in African Americans is not well studied. The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy. Following a 1- to 4-week washout, initial therapy was aliskiren/HCTZ 150/12.5 mg (n=166) or amlodipine 5 mg (n=166) for 1 week, forced-titrated to aliskiren/HCTZ 300/25 mg or amlodipine 10 mg for 7 weeks. Mean seated systolic BP reductions from baseline was similar with both treatments (-28.6 mm Hg with aliskiren/HCTZ vs -28.2 mm Hg with amlodipine). In the substudy, significantly greater reductions in central systolic BP was observed with aliskiren/HCTZ vs amlodipine (-30.1 mm Hg vs -21.2; P=.031), although 24-hour mean ambulatory BP reductions between the two groups were similar. Central pressure is considered an important risk factor in African Americans, and these findings may suggest a new treatment option for these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.